JW (Cayman) Therapeutics Co. Ltd. 2126

HKEX · Hong Kong SAR China · Health Technology

HKD 2.69-0.14 (-4.96%)

Market closed· Oct 2, 2026, 8:08 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

JW (Cayman) Therapeutics Co. Ltd. 2126

HKEX · Hong Kong SAR China · Health Technology

HKD 2.69-0.14 (-4.96%)

Market closed· Oct 2, 2026, 8:08 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+22.60% · 6MFull-screen chart

Open HKD 2.75High HKD 2.85Low HKD 2.66Close HKD 2.68Volume 770.00K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: HKD 2.83
Day range: HKD 2.67 – HKD 2.85
52-week range: HKD 1.40 – HKD 4.68
Volume: 770.00K
Market cap: HKD 1.18B
Next earnings date: 2027-04-01
Avg. volume (1Y): 1.24M

Performance

1 week

-1.83%

1 month

+36.29%

3 months

+39.84%

6 months

+15.73%

Year to date

+7.40%

1 year

-39.25%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Hong Kong SAR China
Exchange: HKEX
Shares outstanding: 405.93M
Employees: 314
ISIN: KYG5210T1040
Beta: 1.87

Technical view

Above averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceOct 31, 2025

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collabora

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.